EATG » Side effects

Side effects

Antiretrovirals do not cause neurodevelopmental harm to uninfected infants

Many infants had prolonged exposure to antiretrovirals, including 18 months of breastfeeding In the first five years of life the neurological development of HIV-exposed but uninfected infants, exposed to maternal…

Major HIV drug calls for vigilance

A study lead by researchers at the Institute of HIV Research, Medical Faculty of UDE and University Hospital Essen, stumbled over a potential toxicity of integrase inhibitors. Integrase Inhibitors (INSTI)…

Efavirenz dose reduction improves lipid profile in adults with HIV-1

Authors of a letter to the editor published in Infectious Diseases contributed to recent Swedish recommendations on the antiviral treatment of HIV infection via a discussion of the association of lowered efavirenz…

Truvada as PrEP tied to only modest bone density decline

A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.  A new, close look at the effect on bone mineral…

HIV drug cabotegravir not associated with weight gain

The novel integrase inhibitor cabotegravir — which is currently in development for both HIV prevention and treatment — was not associated with excess weight gain in HIV-uninfected patients compared with…

Preventing drug induced liver injury in patients with HIV

With an estimated annual incidence rate of 13.9 to 24 per 100,000 inhabitants, drug-induced liver injury (DILI) the leading cause of acute liver failure in the United States. It is…

Dolutegravir-based ART associated with significant weight gain

Treatment-naive patients with HIV who were started on dolutegravir-based ART gained significantly more weight at 18 months compared with those who were started on non-nucleoside reverse transcriptase inhibitor-based and elvitegravir-based…

Dolutegravir-based regimen associated with greater weight gain in treatment-naive individuals

Weight gain associated with antiretroviral therapy (ART), specifically integrase strand transfer inhibitor (INSTI)-based regimens, has been a focus of recent studies, some of which have identified a link between switching…

Dolutegravir during pregnancy appears safe

Dolutegravir treatment does not appear to worsen pregnancy or neonatal outcomes, according to a registry study. "While the results are not conclusive because of the small number of pregnancies, neither…

Weight gain with new antiretrovirals: Its complicated

South Africa’s next big shift in our antiretroviral programme is to replace efavirenz with a newish drug called dolutegravir. The last big change was from stavudine (d4T) to tenofovir, and…

1 2 3 16